EVENTS SCHEDULED FOR TUESDAY 29 MAY
Prof. Charles N. Serhan, Ph.D., D.Sc.
Harvard Medical School
United States of America
Charles is the Simon Gelman Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School, Professor of Oral Medicine, Infection and Immunity at HSDM, and Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital. He received a BS in biochemistry from Stony Brook University followed by a doctorate in experimental pathology and medical sciences from New York University School of Medicine. He was a visiting scientist and post-doctoral fellow at the Karolinska Institutet, Stockholm with Professor Bengt Samuelsson 1982 Nobel Laureate. In 1987, he joined the faculty at Harvard Medical School and received an honorary degree from Harvard University (1996).
He has received several awards including an NIH MERIT award (2000) and has delivered > 50 keynote and plenary lectures. Among these, 2008 William Harvey Outstanding Scientist Medal and AAAS Fellow in 2011. In 2010, he received the Society for Leukocyte Biology-Bonazinga Award, American College of Rheumatology Hench Award Lecture in 2011, and Mérieux 2013 Laureate. In 2016, he received the IUBMB Lecture Metal and the Ross Prize in Molecular Medicine. 2017 Lifetime Achievement Award, International Eicosanoid Research Foundation.
MyBibliography > 530 publications original reports and reviews. Professor Serhan is author of 4 books, and > 463 US patents. H-index: 125; Citations: 55,987. i10 index: 425 (09/15/16).
10:00-10:30 A. Simopoulos
Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk
10:30-10:45 T. Brenna 430756
Dietary implications of a FADS1 regulatory genotype on PUFA synthesis and lipid profiles
10:45-11:15 J. Kang
The omega-6/omega-3 fatty acid imbalance is a critical risk factor for chronic disease
11:15-11:30 E. Baker 447660
Effects of alpha-linolenic acid and linoleic acid on inflammatory mediators in cultured endothelial cells
10:00-10:15 R. Gow 453766 An fMRI study of reward related responses following 16 weeks of omega-3 supplementation in adults with ADHD: The Neuroimaging, Omega-3 and Reward in Adults with ADHD (NORAA) trial
10:15-10:30 J. Hibbeln 447867
Maternal fish consumption during pregnancy and smoking behavioral patterns
10:30-10:45 I. van der Wurff 447468
Results of Food2Learn: a double-blind, randomised, placebo-controlled krill oil supplementation study in adolescents with a low baseline Omega-3 Index
10:45-11:00 K. Hamazaki 416399
Dietary intake of fish and n-3 polyunsaturated fatty acids and risks of perinatal depression: The Japan Environment and Children’s Study (JECS)
11:00-11:15 K. Su 423384
Eicosapentaenoic and docosahexaenoic acids have different effects on peripheral phospholipase A2 gene expressions in acute depressed patients
11:15-11:30 A. Richardson 454584
Key considerations in Clinical Trials of Omega-3 for Child Behaviour and Learning: lessons from the ‘Oxford-Durham’ and ‘Docosahexaenoic Acid Oxford Learning and Behaviour’ Studies
10:00-10:30 G. Kunos (Keynote)
Endocannabinoids, CB1 receptors and the metabolic syndrome (30 min)
10:30-10:45 J. Kaplan 447653
Dietary Fatty Acid Composition Drives Obesity-Associated Insulin Resistance
10:45-11:00 H. Fisk 422484
The effect of obesity on adipose tissue fatty acid composition and lipid mediators, and their response to chronic marine omega-3 fatty acid supplementation: The BIOCLAIMS
11:00-11:15 C. Damsgaard 432956
PPARG and APOE polymorphisms modify associations between n-3 LCPUFA and plasma lipid profile and insulin in 8-11 year-old children
11:15-11:30 A. Ibrahim 432686
Partial replacement of dietary linoleic acid with α- linolenic acid or long chain n-3 polyunsaturated fatty acids prevents fructose-induced metabolic syndrome via attenuating adipose tissue inflammation and oxidative stress
Prof. Erik Ingelsson
United States of America
Dr. Ingelsson obtained his MD (2000) and PhD (2005) at Uppsala University, Sweden. After internship, he did a residency in general medicine (2003-2006) and took up a postdoctoral research fellowship at the Framingham Heart Study (2006-2007). He moved to Karolinska Institutet (Stockholm, Sweden) in 2007 and was appointed Professor of Cardiovascular Epidemiology in 2010. From 2013-2016, he was a Professor of Molecular Epidemiology at Uppsala University. He was also a Visiting Professor at the Wellcome Trust Centre for Human Genetics at University of Oxford in 2012-2015. Since May 2016, he is Professor of Medicine at Stanford University.
His main area of interest is the link between metabolic disturbances, such as obesity and insulin resistance, and the development of subclinical and clinical cardiovascular disease. His research is translational and interdisciplinary, combining methods from the molecular epidemiology field - such as genomic, metabolomic, transcriptomic, epigenomic and proteomic profiling in large population-based studies - with in vivo and in vitro work to reach new insights into the pathophysiology of cardiovascular disease and related conditions, identification of new biomarkers for improved risk prediction, and discovery of novel targets for drug development.
He has had a leading role in many of the large efforts identifying new loci associated with cardiovascular and metabolic traits, and has extensive experience from research on biomarkers and -omics methods, including development and use of prediction metrics and Mendelian randomization. He has served as PI of numerous –omics efforts in several Swedish cohort studies, including ULSAM, PIVUS, TwinGene and EpiHealth. Since 2014 and on, he has also built a team working with characterization of loci established in GWAS using different functional model systems. He has published over 230 peer-reviewed publications, of which >50 in journals with impact factor over 30. Before relocating to the U.S, he received many European research grants, and now after joining the Stanford faculty in May 2016, he has received his my first NIH grants. He has won several prestigious awards and grants, such as the AHA Trudy Bush Fellowship for Cardiovascular Research in Women’s Health, ERC starting grant, Wallenberg Academy Fellow and the Göran Gustafsson Prize in Medicine in 2015 (to the most successful medical researcher in Sweden under age 45).
On his spare time, he likes to spend time with his family (wife Maria, Hugo, 12 and Alice, 10 years old) and friends; enjoys cooking, but also eating nice food and wine; tries to make his daily running routine; and sings in choirs - amongst others, the San Francisco Symphony Chorus.
2:30-2:45 C. Chiu 447741
Genetic variation in FADS genes is associated with cognitive function in people with late-life depression
2:45-3:00 J. SanGiovanni 445011
Twelve novel genetic loci associated with plasma EPA and DHA
3:00-3:15 D. Li 438834
Replication of a gene-diet interaction at CD36, NOS3 and PPARG in response to n-3 PUFA supplementation on blood lipids: a double-blind randomized controlled trial
3:15-3:30 B. Hopiavuori 421979
Homozygous Expression of Mutant ELOVL4 Leads to Seizures and Death in a Novel Animal Model of Very Long-Chain Fatty Acid Deficiency
3:30-3:45 P. Kane 446931
Use of Pro-Resolving Bioactive Lipids to Address Aberrant Interplay among Organelles following Epigenetic Insult in Neuromuscular Disease
3:45-4:00 J. Perez-Mojica 446416
Methylome and transcriptome changes are related to the reduced proliferation and cell death induced by docosahexaenoic acid in Jurkat cells.
2:30 - 3:00 M. Makrides 448493
Optimising trial designs for fatty acid intervention studies (30min)
3:00 - 3:30 K. Best 448694
Planning for success: Strategies for effective operationalization of a clinical trial protocol (30min)
3:30 - 4:00 E. Kerling 443664
Keeping the Train on the Tracks: How to Efficiently Execute an Ongoing Clinical Trial (30min)
2:30-2:45 A. Dumont 446309
Docosahexaenoic acid controls 5-Fluorouracil-mediated NLRP3 inflammasome activation in myeloid-derived suppressor cells
2:45-3:00 E. Kim 431627
Increased plasma membrane order associated with oncogenic Apc and Kras signaling promotes cell proliferation in colonocytes
3:00-3:15 Q. Escoula 446306
Endogenous omega 3 fatty acids prevent gut microbiota dysbiosis, colon mucus layer thickness alteration and endoplasmic reticulum stress induced by high-fat high-sucrose diet
3:15-3:30 M. Mbarik 448444
Impact of steroid hormones on the expression of fatty acid desaturases and elongases in hormone-dependent carcinoma cell lines
3:30-3:45 J. Li 425057
Maternal n-3 polyunsaturated fatty acids diet during pregnancy decreases mammary cancer risk of female offspring
3:45-4:00 A. Bhullar 445888
Altered lipid composition of fat infiltrated skeletal muscle of cancer patients
4:30-4:45 A. Kasonga 402430
Free fatty acid receptor 4 mediates the anti-osteoclastogenic effect of unsaturated fatty acids through ß-arrestin 2 signalling pathways
4:45-5:00 K. Gawrisch 448481
How does cholesterol modulate function of G protein-coupled membrane receptors?
5:00-5:15 A. Taha 448506
Linoleic acid entering the brain is rapidly metabolized into oxidized metabolites that regulate neuronal signaling
5:15-5:30 M. Uttley 445654
Modelling the Network of Eicosanoids in Human Skin Cells
5:30-5:45 M. Ferreira 446436
Discovering the influence of 15-Lipoxygenase and its Metabolites in Glioblastoma Growth and Migration/Invasion
5:45-6:00 S. Bhattacharjee 433401
The novel lipid mediators, elovanoids, target telomerase signaling in human retinal pigment epithelial cells.
4:30-5:00 D. Lovinger (Keynote)
Endocannabinoid Roles in Brain Function and Behavior (30 min)
5:00-5:15 M. Lagarde 445961
Biosynthesis of N-docosahexaenoylethanoylamine studied by mass spectrometry
5:15-5:30 B. Huang 402430
Molecular mechanism of synaptamide-mediated GPR110 activation probed by in-cell crosslinking, mass spectrometry and structural modeling
5:30-5:45 L. Lin 447948
Dietary fatty acids augment tissue levels of endocannabinoids in n-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) knockout mice
5:45-6:00 A. Nicolau 447342
Chronic inflammatory arthritis drives system-wide changes in the circadian regulation of bioactive lipids
4:30-5:00 R. DeGroot/B. Meyer
Factors that influence omega-3 long chain polyunsaturated fatty acid levels in human blood – A Systematic Literature Review (30 min)
5:00-5:30 Tom Brenna/M. Pourde 458484
ILSI Fatty Acid Best Practices Project: Introduction, Study Design and interpretation (30 min)
5:30-6:00 K. Stark
FABP Laboratory Analysis and reporting (30 min)
Special Interest Group Invitation & Confirmed Groups
ISSFAL invites proposals for Special Interest Group meetings at the 2018 Biennial Congress in Las Vegas, May 27th – 31st.
This is an opportunity to have small group meetings on specialized topics for in-depth discussion, peer formation, particularly for younger generation professionals including students, and first-hand information sharing. Lipid-related basic and clinical research topics are welcome. Once the proposals are accepted, they will be posted on the web-page to attract participants. Any interest group attracting at least 15 participants will be offered a meeting room with podium, AV equipment and desserts/refreshments on the evening of Tuesday May 29th starting at 7:00 PM.
For initial evaluation, a one-paragraph proposal describing the background and justification should be submitted to the Congress Chair, Hee-Yong Kim at email@example.com
Hee-Yong Kim, Ph.D.
Chief, Laboratory of Molecular Signaling
Challenges in lipid trafficking and metabolism
Hosted by: Chuck Chen, Blake Hopiavuori, and Kevin Lin
A major challenge we face as lipid biologists, is the inability to accurately and reproducibly track lipids as they are trafficked intracellularly. Cellular membranes have unique lipid profiles, but for example, how do cells distinguish between a 26:0-containing (dihydro) ceramide and a 22:6n3-containing phosphatidylcholine? Are there unique chaperones for specific lipids? How are lipid molecules recognized by such chaperones? Is it based on the electron cloud signature of a specific lipid or purely structural configurations?
Similar to proteins, the objective of the Lipid Trafficking Interest Group is to target, track, and identify unique lipid molecules to better understand how lipids are involved in various pathological conditions. A better understanding of lipid biochemistry may be the key to understanding the most complicated human diseases. Come share your thoughts and ideas with us as we embark on this complicated yet exciting journey. Refreshments will be served.
Lipidomics Special Interest Group
Hosted by: Juan J. Aristizabal Henao and Alexander Sorokin
Lipidomics requires advanced expertise in lipid metabolism and analytical chemistry. Rapid changes in technology, such as mass spectrometry instruments and software to process the data add to the challenges in the field, particularly for graduate students. The use of lipidomics can provide unique insights into the various influences on lipid biology such as nutrition and genetics and help elucidate metabolic pathways in the study of health and disease. This session will provide a place where graduate students, young professionals and researchers can talk frankly about their experiences with lipidomics and some of the challenges they have encountered. The forum would be open, but could entail discussions on types of analytical approaches, sample preparation, challenges with quantitation, and identification of lipids species in untargeted analyses. In addition, the forum would be interested in discussions with individuals looking to make the leap from fatty acid composition type analyses to lipidomic analyses that identify the acyl/alkyl species of complex lipids in their naïve form.